Crossmark

Economic and Treatment Burden of Chronic Low-Back Pain Patients Transitioning from Short-Acting to Long-Acting Opioids or Buprenorphine Buccal Film: US Claims Analysis

Crossref DOI link: https://doi.org/10.1007/s40122-026-00815-0

Published Online: 2026-02-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Stanicic, Filip https://orcid.org/0000-0003-2293-8940
Grbic, Dimitrije https://orcid.org/0009-0005-4962-4396
Zah, Vladimir https://orcid.org/0000-0003-1368-4491
Funding

Funding for this research was provided by:

Collegium Pharmaceutical Inc.
License Information

Text and Data Mining valid from 2026-02-08

Version of Record valid from 2026-02-08
More Information

Article History

Received: 26 November 2025

Accepted: 8 January 2026

First Online: 8 February 2026

Declarations

:

: Filip Stanicic, Dimitrije Grbic, and Vladimir Zah are employees of ZRx Outcomes Research Inc. ZRx Outcomes Research Inc. received funding from Collegium Pharmaceutical Inc. for conducting this study. The funding source did not have any direct or indirect impact on study findings.

: The Merative MarketScan ® insurance claims database used for this analysis complies with the Health Insurance Portability and Accountability Act of 1996 (HIPAA), protecting patients’ privacy and ensuring the confidentiality of personal data. Since all data within the abovementioned database are de-identified, approval of the institutional review board or the ethics committee for conducting the research was not required.

Document is current

Any future updates will be listed below